000			03710nam a22003855i 4500
001			394769
003			ES-MaUEC
005			20230102123158.0
007			cr nn 008mamaa
008			220721s2022 sz | s |||| 0|eng d
020			_a9783030999957
024	7		_a10.1007/978-3-030-99995-7 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
245	1	0	_aFrom Obesity to Diabetes _cedited by Juergen Eckel, Karine Clément
250			_a1st edition 2022
264		1	_aCham _bSpringer International Publishing _c2022
300			_a1 recurso en línea (VIII, 513 páginas) _b1 illus
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aHandbook of Experimental Pharmacology _x1865-0325 _v274
505	0		_aPart I Obesity. Epidemiology of Obesity -- The Circadian Clock and Obesity -- Nutrition and Microbiome -- From Obesity to Diabetes: The Role of the Adipose Organ -- Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy -- The Enteroendocrine System in Obesity -- Insights from Studies of White Adipose Tissue Using Single-Cell Approaches -- Obesity-Related Insulin Resistance: The Central Role of Adipose Tissue Dysfunction -- Obesity, Senescence, and Senolytics -- Obesity and Obstructive Sleep Apnea -- Part II Diabetes and Complications. Inter-Organ Crosstalk in the Development of Obesity-Associated Insulin Resistance -- Islet Inflammation and β Cell Dysfunction in Type 2 Diabetes -- NAFLD and NASH: The Metabolically Diseased Liver -- Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities -- Diabetic Peripheral Neuropathy -- Part III Lifestyle Modifications and Future Treatments. Weight Loss Strategies -- Physical Activity, Obesity and Weight Loss Maintenance -- Bariatric/Metabolic Surgery -- Drugs for Treating Obesity -- Novel Drugs for Diabetes Therapy -- Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function -- Precision Medicine and Obesity -- Targeting the Enteroendocrine System for Treatment of Obesity.
520			_aObesity is a major risk factor for the development of type 2 diabetes and its associated complications, a major socio-economic burden for health care systems. The worldwide prevalence of obesity doubled since 1980 and as a consequence the number of patients with diabetes has been continuously rising with more than 450 Mio. people suffering from this disease at the present time. Substantial progress has been made in understanding the molecular pathways leading from excessive fat accumulation to metabolic perturbation and finally diabetes manifestation. This edition of the "Handbook of Experimental Pharmacology" aims to analyze new insight into the pathophysiology of obesity, to decipher the complex links to diabetes and its complications, and to collect most recent information on new strategies for prevention and treatment of obesity and diabetes.
700	1		_aEckel, Juergen _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aClément, Karine _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030999940
776	0	8	_iPrinted edition: _z9783030999964
776	0	8	_iPrinted edition: _z9783030999971
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-99995-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
988			_aSpringer_BiomedLife_2022
999			_c394769 _d394769